late-relapsing hepatitis after yellow fever

Clicks: 270
ID: 146451
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #148 of 245 articles by views in International journal of pharmaceutics

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
One patient presented hyporexia, asthenia, adynamia, and jaundice two months after acute yellow fever (YF) onset; plus laboratory tests indicating hepatic cytolysis and a rebound of alanine and aspartate transaminases, and total and direct bilirubin levels. Laboratory tests discarded autoimmune hepatitis, inflammatory or metabolic liver disease, and new infections caused by hepatotropic agents. Anti-YFV IgM, IgG and neutralizing antibodies were detected in different times, but no viremia. A liver biopsy was collected three months after YF onset and tested positive for YFV antigens and wild-type YFV-RNA (364 RNA-copies/gram/liver). Transaminases and bilirubin levels remained elevated for five months, and the arresting of symptoms persisted for six months after the acute YF onset. Several serum chemokines, cytokines, and growth factors were measured. A similar immune response profile was observed in the earlier phases of the disease, followed by more pronounced changes in the later stages, when transaminases levels returned to normal. The results indicated viral persistence in the liver and continual liver cell damage three months after YF onset and reinforced the need for extended follow-ups of YF patients. Further studies to investigate the role of possible viral persistence and the immune response causing relapsing hepatitis following YF are also necessary.
Reference Key
rezende2020viruseslate-relapsing Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Izabela Maurício Rezende;Leonardo Soares Pereira;Jordana Rodrigues Barbosa Fradico;Marcelo Antônio Pascoal Xavier;Pedro Augusto Alves;Ana Carolina Campi-Azevedo;Elaine Speziali;Lívia Zignago Moreira dos Santos;Natalia Soares Albuquerque;Indiara Penido;Tayrine Araujo Santos;Ana Paula Dinis Ano Bom;Andrea Marques Vieira da Silva;Camilla Bayma Fernandes;Carlos Eduardo Calzavara;Erna Geessien Kroon;Olindo Assis Martins-Filho;Andréa Teixeira-Carvalho;Betânia Paiva Drumond
Journal International journal of pharmaceutics
Year 2020
DOI
10.3390/v12020222
URL
https://www.mdpi.com/1999-4915/12/2/222
Keywords
hepatitis liver damage yellow fever

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.